Any current/future new fundraising through debt or equity?

The company has planned a rights issue in the near future to address liquidity and working capital challenges (Page 4). The rights issue is intended to recoup losses and support working capital needs (Page 9). No immediate plans to reduce existing debt, but the company aims not to increase debt further and stabilize business first (Page 4). Current gross debt is around INR750 crores; net debt approximately INR650 crores; includes short-term working capital of ~INR300 crores and long-term debt of ~INR440 crores (Page 4). No indication of new debt fundraising currently; focus is on restr

Any current/future capex/capital investment/strategic investment?

The company is currently running vanillin capacity at 40% and plans to scale up to 50% in the next year, with an aim to reach 100% utilization eventually. There are no immediate plans to expand vanillin capacity beyond the existing 6,000 tons. Focus is on optimizing current capacities before considering further expansion. No mention of other specific capital expenditures or strategic investments in the near term. The management is concentrating on growing existing businesses like Blends and Aroma, improving utilization, and awaiting clarity on antidumping duties before entering into lo

Future growth expectations in sales/revenue/volumes?

Blends business expected to grow at ~20% YoY for next couple of years; target to increase revenue from INR220 crores to INR300 crores over 4-5 quarters. Aroma business planned to ramp up capacity utilization from 40% to 55% by FY '25-end, reaching 75% by FY '26 and eventually 100%; revenue expected to grow from INR40-45 crores to around INR80-100 crores. Performance Chemicals (hydroquinone, catechol) expected to grow 15-20% in next financial year; current utilization at 80%, with expansion tied to downstream demand. Blends revenue in Europe about INR18 crores currently with growth focus; aim t

Future growth expectations in earnings/operating earnings/profits/EPS?

Revenue for FY '26 is expected to be in the range of INR 2,300 to INR 2,400 crores. EBITDA margins are anticipated to remain in the teens, with mid-teens possible but difficult to predict due to pricing uncertainties. EBITDA margins improved to 10.2% in Q2 FY '25, with expectations to maintain or modestly improve margins in H2 FY '25. Savings from European facility shutdown likely to increase EBITDA margins by about 4% but only after two quarters. Blends business projected to grow ~20% annually over next few years, supporting top-line growth. Aroma business capacity utilization expec

Camlin FineQ2 FY25Chemicals & Petrochemicals

Camlin Fine Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹91Market Cap: ₹1.9K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

Blends business expected to grow at ~20% YoY for next couple of years; target to increase revenue from INR220 crores to INR300 crores over 4-5 quarters.
Aroma business planned to ramp up capacity utilization from 40% to 55% by FY '25-end, reaching 75% by FY '26 and eventually 100%; revenue expected to grow from INR40-45 crores to around INR80-100 crores.
Performance Chemicals (hydroquinone, catechol) expected to grow 15-20% in next financial year; current utilization at 80%, with expansion tied to downstream demand.
Blends revenue in Europe about INR18 crores currently with growth focus; aim to increase footprint and volume.
Overall revenue guidance for FY '26 likely around INR2,300-2,400 crores.
EBITDA margins expected to remain in mid-teens, though pricing and market factors make exact margin prediction difficult.

Margin guidance

Category 3

Revenue for FY '26 is expected to be in the range of INR 2,300 to INR 2,400 crores.
EBITDA margins are anticipated to remain in the teens, with mid-teens possible but difficult to predict due to pricing uncertainties.
EBITDA margins improved to 10.2% in Q2 FY '25, with expectations to maintain or modestly improve margins in H2 FY '25.
Savings from European facility shutdown likely to increase EBITDA margins by about 4% but only after two quarters.
Blends business projected to grow ~20% annually over next few years, supporting top-line growth.
Aroma business capacity utilization expected to rise from current ~40% to 75%-80% by FY '26, reaching full capacity later.
Performance Chemicals segment anticipated to grow 15%-20% with new value-added products.
No further major impairments anticipated; working capital and liquidity remain focus areas.
Rights issue planned to support working capital and stabilize operations.

See what Camlin Fine management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

The company has planned a rights issue in the near future to address liquidity and working capital challenges (Page 4).
The rights issue is intended to recoup losses and support working capital needs (Page 9).
No immediate plans to reduce existing debt, but the company aims not to increase debt further and stabilize business first (Page 4).
Current gross debt is around INR750 crores; net debt approximately INR650 crores; includes short-term working capital of ~INR300 crores and long-term debt of ~INR440 crores (Page 4).
No indication of new debt fundraising currently; focus is on restructuring existing loans, especially in Europe (Page 5).
No specific timeline or quantum mentioned for the rights issue beyond "very near future" (Page 4).

Order book

The transcript does not explicitly provide specific figures or detailed commentary on the current or expected order book or pending orders for Camlin Fine Sciences Limited. However, insights can be inferred: - The company is seeing steady growth in the Blends business with expectations to grow it by about 20% year over year. - Aroma business is improving, currently operating at about 40-50% capacity, aiming to reach 75-80% capacity over the next couple of years, with continued demand. - Confidence expressed about revenue growth for FY '26 around INR 2,300-2,400 crores. - Contracts in Aroma business are typically short-term (quarterly or half-yearly) due to antidumping duty uncertainty, suggesting order visibility is currently short term. - No mention of long-term contracts being signed until antidumping duties are finalized. - The Europe facility shutdown impacts current revenue and EBITDA but is expected to stabilize. No explicit quantitative pending orderbook or backlog figures were disclosed.

See what Camlin Fine management said on order book — free account, 30 seconds.

Capex plans

Yes

The company is currently running vanillin capacity at 40% and plans to scale up to 50% in the next year, with an aim to reach 100% utilization eventually.
There are no immediate plans to expand vanillin capacity beyond the existing 6,000 tons.
Focus is on optimizing current capacities before considering further expansion.
No mention of other specific capital expenditures or strategic investments in the near term.
The management is concentrating on growing existing businesses like Blends and Aroma, improving utilization, and awaiting clarity on antidumping duties before entering into long-term contracts or making new investments.
There is mention of restructuring efforts and rights issue planned to strengthen working capital and stabilize the business, not specifically for new capex.

Track Camlin Fine — get its next earnings analysis in your feed

How does Camlin Fine rank vs peers in Chemicals & Petrochemicals?

Pro feature

ThisCamlin Fine

Rev 3Mar 3

See where Camlin Fine sits in Chemicals & PetrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Camlin Fine rank in Chemicals & Petrochemicals?

Compare Camlin Fine against every Chemicals & Petrochemicals company (Q2 FY25) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

What Camlin Fine's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

Prasol Chemicals Ltd (Q1 FY27)
Q1 FY27 Revenue from Operations: ₹433.6 crores . Key investor presentation takeaways from Prasol Chemicals Ltd's Q1 FY27 investor presentation — and how it rank
Vipul Organics Ltd (Q4 FY26)
Q4 FY26 (Mar 2026) total revenue: ₹5,262.37 lakhs (Consolidated) . Key concall takeaways from Vipul Organics's Q4 FY26 earnings call — and how it ranks against…
Vipul Organics Ltd (Q1 FY27)
Q1 FY27 net revenue: ₹51.78 crore, up +37.7% YoY (Page 13) . Key concall takeaways from Vipul Organics's Q1 FY27 earnings call — and how it ranks against…
Fine Organic Industries Ltd (Q1 FY27)
Revenue from Operations (Consolidated) for Q1FY27: Rs 694.2 Cr, up 18.0% YoY from Rs 588.4 Cr in Q1FY26 (Page 34). Key concall takeaways from Fine Organic…

Compare:vs Solar Industries India Ltd vs Pidilite Inds.vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Camlin Fine Q2 FY25 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Camlin Fine rank in Chemicals & Petrochemicals?

Continue your research

What Camlin Fine's management said in earlier quarters

Others in Chemicals & Petrochemicals this season